These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 37587493)

  • 1. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
    Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
    Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
    Siebert S; Coates LC; Schett G; Raychaudhuri SP; Chen W; Gao S; Seridi L; Chakravarty SD; Shawi M; Lavie F; Sharaf M; Zimmermann M; Kollmeier AP; Xu XL; Rahman P; Mease PJ; Deodhar A
    Arthritis Rheumatol; 2024 Jun; 76(6):894-904. PubMed ID: 38253404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
    Ogdie A; Merola JF; Mease PJ; Ritchlin CT; Scher JU; Lafferty KP; Chan D; Chakravarty SD; Langholff W; Wang Y; Choi O; Krol Y; Gottlieb AB
    BMC Rheumatol; 2024 May; 8(1):20. PubMed ID: 38773563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials.
    Sweet K; Song Q; Loza MJ; McInnes IB; Ma K; Leander K; Lakshminarayanan V; Franks C; Cooper P; Siebert S
    RMD Open; 2021 May; 7(2):. PubMed ID: 34011674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
    Coates LC; Gossec L; Theander E; Bergmans P; Neuhold M; Karyekar CS; Shawi M; Noël W; Schett G; McInnes IB
    Ann Rheum Dis; 2022 Mar; 81(3):359-369. PubMed ID: 34819273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
    Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
    Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.
    Siebert S; Sweet K; Dasgupta B; Campbell K; McInnes IB; Loza MJ
    Arthritis Rheumatol; 2019 Oct; 71(10):1660-1669. PubMed ID: 31070869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
    Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
    Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.
    Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Schiopu E; Chakravarty SD; Kollmeier AP; Xu XL; Shawi M; Jiang Y; Sheng S; Wang Y; Xu S; Merola JF; McInnes IB; Deodhar A
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35296534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
    Ritchlin CT; Helliwell PS; Boehncke WH; Soriano ER; Hsia EC; Kollmeier AP; Chakravarty SD; Zazzetti F; Subramanian RA; Xu XL; Zuraw QC; Sheng S; Jiang Y; Agarwal P; Zhou B; Zhuang Y; Shawi M; Karyekar CS; Deodhar A
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33568556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
    Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Xu S; Quinn ST; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar A; Østergaard M; Baraliakos X
    Trials; 2022 Sep; 23(1):743. PubMed ID: 36064592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.
    Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Chakravarty SD; Rampakakis E; Shawi M; Schiopu E; Merola JF; McInnes IB; Deodhar A
    Clin Rheumatol; 2024 Aug; 43(8):2551-2563. PubMed ID: 38844682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor.
    Izumiyama T; Mori Y; Oizumi I; Hamada S; Kurishima H; Terui H; Omori-Shimada R; Yamasaki K; Itoi E
    J Orthop Surg (Hong Kong); 2021; 29(2):23094990211012286. PubMed ID: 33938296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Warren RB; McInnes IB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; Mease PJ
    Rheumatol Ther; 2024 Jun; 11(3):829-839. PubMed ID: 38488975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.
    Ritchlin CT; Deodhar A; Boehncke WH; Soriano ER; Kollmeier AP; Xu XL; Zazzetti F; Shawi M; Jiang Y; Sheng S; Helliwell PS
    ACR Open Rheumatol; 2023 Mar; 5(3):149-164. PubMed ID: 36762512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
    Mease PJ; McInnes IB; Tam LS; Eaton K; Peterson S; Schubert A; Chakravarty SD; Parackal A; Karyekar CS; Nair S; Boehncke WH; Ritchlin C
    Rheumatology (Oxford); 2021 May; 60(5):2109-2121. PubMed ID: 33844022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
    Rahman P; Mease PJ; Helliwell PS; Deodhar A; Gossec L; Kavanaugh A; Kollmeier AP; Hsia EC; Zhou B; Lin X; Shawi M; Karyekar CS; Han C
    Arthritis Res Ther; 2021 Jul; 23(1):190. PubMed ID: 34261541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
    Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
    Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.